Mutational Landscape of Patients Treated With TG4050, an Individualised Neoantigen Therapeutic Vaccine In Early-Stage Cancer Treatment

• Phase 1 study of a viral-vectored individualised neoantigen vaccine in HNSCC
• Dive deeper into the mutational landscape of the patient population and factors influencing vaccine composition
• Immunogenicity of vaccine neoantigens and potential validation of bioinformatic prediction approach

Speakers:

Maurizio Ceppi

Chief Scientific Officer

Transgene